Cargando…

In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to improve cardiovascular outcomes when added to conventional statin therapy. This study aims to investigate the efficacy and safety of in-hospital initiation of PCSK9 inhibitors among patients with acute my...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lou, Bowen, Liu, Hui, Luo, Yongbai, Jiang, Gulinigaer Tuerhong, Wu, Haoyu, Wang, Chen, Wu, Yue, Zhou, Bo, Yuan, Zuyi, She, Jianqing, Liu, Junhui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9590135/ https://www.ncbi.nlm.nih.gov/pubmed/36280861 http://dx.doi.org/10.1186/s12944-022-01724-9

Ejemplares similares

ARNI versus ACEI/ARB in Reducing Cardiovascular Outcomes after Myocardial Infarction
por: She, Jianqing, et al.
Publicado: (2021)

Association between Cystatin C and Cardiac Function in Acute Myocardial Infarction Patients: A Real-World Analysis
por: Lou, Bowen, et al.
Publicado: (2022)

Circulating lipid and lipoprotein profiles and their correlation to cardiac function and cardiovascular outcomes in patients with acute myocardial infarction
por: Wu, Haoyu, et al.
Publicado: (2021)

Clinical characteristics and protective factors in patients with acute myocardial infarction undergoing in-hospital myocardial free wall rupture: a single-center, retrospective analysis
por: Lou, Bowen, et al.
Publicado: (2019)

Interplay Between Gut Microbiota and Amino Acid Metabolism in Heart Failure
por: Tuerhongjiang, Gulinigaer, et al.
Publicado: (2021)

Dysregulated Arginine Metabolism in Young Patients with Chronic Persistent Asthma and in Human Bronchial Epithelial Cells
por: Zhou, Bo, et al.
Publicado: (2021)

PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation
por: Andreadou, Ioanna, et al.
Publicado: (2020)

Serum lipids profiling perturbances in patients with ischemic heart disease and ischemic cardiomyopathy
por: Yang, Lin, et al.
Publicado: (2020)

Cardiotoxicity Related to Immune Checkpoint Inhibitors: A Real-World Retrospective Analysis
por: She, Jianqing, et al.
Publicado: (2022)

Increased circulating uric acid aggravates heart failure via impaired fatty acid metabolism
por: Lou, Bowen, et al.
Publicado: (2023)

HDL-C/apoA-I Ratio Is Associated with the Severity of Coronary Artery Stenosis in Diabetic Patients with Acute Coronary Syndrome
por: Sun, Lizhe, et al.
Publicado: (2021)

Circulating PCSK9 and Risk of Myocardial Infarction: The HUNT Study in Norway
por: Laugsand, Lars E., et al.
Publicado: (2016)

Sex Differences Associated With Circulating PCSK9 in Patients Presenting With Acute Myocardial Infarction
por: Zhang, Zhong, et al.
Publicado: (2019)

Correlation of Triiodothyronine Level with In-Hospital Cardiac Function and Long-Term Prognosis in Patients with Acute Myocardial Infarction
por: She, Jianqing, et al.
Publicado: (2018)

Serum metabolite profiles as potential biochemical markers in young adults with community-acquired pneumonia cured by moxifloxacin therapy
por: Zhou, Bo, et al.
Publicado: (2020)

Pcsk9 is associated with severity of coronary artery lesions in male patients with premature myocardial infarction
por: Gao, Jing, et al.
Publicado: (2021)

Hemoglobin A(1c) is associated with severity of coronary artery stenosis but not with long term clinical outcomes in diabetic and nondiabetic patients with acute myocardial infarction undergoing primary angioplasty
por: She, Jianqing, et al.
Publicado: (2017)

Impact of Age, Sex, and Renal Function on the Efficacy and Safety of Direct Oral Anticoagulants vs. Vitamin K Antagonists for the Treatment of Acute Venous Thromboembolism: A Meta-Analysis of 22,040 Patients
por: Zhou, Bo, et al.
Publicado: (2021)

Association and differences in genetic polymorphisms in PCSK9 gene in subjects with lacunar infarction in the Han and Uygur populations of Xinjiang Uygur Autonomous Region of China
por: Han, Deng-feng, et al.
Publicado: (2017)

Blood lipid-related low-frequency variants in LDLR and PCSK9 are associated with onset age and risk of myocardial infarction in Japanese
por: Tajima, Tomoyuki, et al.
Publicado: (2018)

PCSK9 Modulates Macrophage Polarization-Mediated Ventricular Remodeling after Myocardial Infarction
por: Wang, Feifei, et al.
Publicado: (2022)

PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017)

Targeting amino acids metabolic profile to identify novel metabolic characteristics in atrial fibrillation
por: She, Jianqing, et al.
Publicado: (2018)

Development and Evaluation of a Risk Prediction Model for Left Ventricular Aneurysm in Patients with Acute Myocardial Infarction in Northwest China
por: Xing, Yuanming, et al.
Publicado: (2022)

Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries
por: Colivicchi, Furio, et al.
Publicado: (2020)

PCSK9 targets important for lipid metabolism
por: Schulz, Rainer, et al.
Publicado: (2017)

Plasma PCSK9 Levels Are Elevated with Acute Myocardial Infarction in Two Independent Retrospective Angiographic Studies
por: Almontashiri, Naif A. M., et al.
Publicado: (2014)

PCSK 9 Inhibitors: A Short History and a New Era of Lipid-lowering Therapy
por: Hajar, Rachel
Publicado: (2019)

Altered exosomal microRNA profiles in bronchoalveolar lavage fluid can mediate metabolism in patients with Acinetobacter baumannii ventilator-associated pneumonia
por: Zhou, Bo, et al.
Publicado: (2020)

Correlation of PCSK9 Gene Polymorphism with Cerebral Ischemic Stroke in Xinjiang Han and Uygur Populations
por: Han, Dengfeng, et al.
Publicado: (2014)

Lipid Lowering Therapy and Circulating PCSK9 Concentration
por: Nozue, Tsuyoshi
Publicado: (2017)

Feasibility of Short-Term Aggressive Lipid-Lowering Therapy with the PCSK9 Antibody in Acute Coronary Syndrome
por: Yamashita, Satoshi, et al.
Publicado: (2023)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

PCSK9 Promotes Cardiovascular Diseases: Recent Evidence about Its Association with Platelet Activation-Induced Myocardial Infarction
por: Puteri, Meidi Utami, et al.
Publicado: (2022)

PCSK9 and Other Metabolic Targets to Counteract Ischemia/Reperfusion Injury in Acute Myocardial Infarction and Visceral Vascular Surgery
por: Ortona, Silvia, et al.
Publicado: (2022)

Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations
por: Mayne, Janice, et al.
Publicado: (2013)

Serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk and lipid profiles in southern Chinese Han population
por: Cai, Gaojun, et al.
Publicado: (2018)

Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
por: Cao, Ye-Xuan, et al.
Publicado: (2019)

Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation
por: LaFratte, Christopher, et al.
Publicado: (2023)

Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo
por: Schreckenberg, Rolf, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_09l83tlj01ebhh0clvlphh9gjl